Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act 1934
Date of
Report (date of earliest event reported): June 1, 2010
JIANGBO
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
Florida
(State or
other jurisdiction of incorporation)
|
333-86347
|
65-1130026
|
|
(Commission File
Number)
|
(IRS Employer Identification
No.)
|
|
25 Haibe Road, Laiyang Economic
Development Zone,
|
|
Laiyang
City, Yantai, Shandong Province, People’s Republic of China
265200
|
(Address
of principal executive offices and zip code)
(0086)535-7282997
(Registrant's
telephone number including area code)
GENESIS PHARMACEUTICALS ENTERPRISES,
INC.
(Registrant's
former name or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR
240.14a-12(b))
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other
Event.
On June
4, 2010, Jiangbo Pharmaceuticals, Inc. (the “Company”) issued a
press release announcing that it had been approved for listing on The Nasdaq
Global Market and would commence trading under the symbol “JGBO” on June 8,
2010. A copy of the press release is attached hereto as Exhibit
99.1.
Item
9.01 Financial Statements
and Exhibits.
|
Exhibit No.
|
Description
|
| |
|
|
99.1
|
Press
Release dated June 4,
2010.
|
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
| |
JIANGBO PHARMACEUTICALS,
INC. |
|
| |
|
|
|
|
|
By:
|
/s/ Elsa
Sung |
|
| |
Name: |
Elsa
Sung |
|
| |
Title: |
Chief
Financial Officer |
|
| |
|
|
|
Dated: June 4, 2010